Identification of the binding roles of terminal and internal glycan

epitopes using enzymatically synthesized N-glycans containing tandem

epitopes

Zhigang Wu, ^a Yunpeng Liu, ^a Cheng Ma, ^a Lei Li, ^a Jing Bai, ^b Lauren Byrd-Leotis, ^c Yi Lasanajak, ^d Yuxi Guo,^a Liuqing Wen,^a He Zhu,^a Jing Song,^a Yanhong Li,^e David A. Steinhauer,^c David F. Smith,^d Baohua Zhao,^b Xi Chen,^{*e} Wanyi Guan^{*ab} and Peng George Wang^{*a}

^aDepartment of Chemistry and Center of Diagnostics & Therapeutics, Georgia State University, Atlanta, GA 30303, USA

^bCollege of Life Science, Hebei Normal University, Shijiazhuang, Hebei 050024, China

^cDepartments of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA

^dDepartment of Biochemistry and Emory Comprehensive Glycomics Core, Emory University School of Medicine, Atlanta, GA 30322, USA

^eDepartment of Chemistry, University of California, Davis, CA 95616, USA

Supporting Information

Table of Contents

I. Materials and enzymes	S2
II. General methods for glycan preparation	S2
III. General methods for HPLC analysis and purification of N-glycans	S11
IV. General methods for mass spectrometry analysis	S13
V. General methods for glycan microarray assay	S13
VI. HPLC profiles, MS and NMR data of purified <i>N</i> -glycans	S14
VII. NMR spectra of purified N-glycans	S50
VIII. References	S86 51

I. Materials and enzymes

N-Glycolylneuraminic acid (Neu5Gc) and cytidine 5'-triphosphate (CTP) were purchased from Carbosynth Limited. Cyanine 5 (Cy5)-streptavidin was from Invitrogen. FastAP was from Promega. Monoclonal anti-CD15s (sialyl Lewis x, sLe^x) antibody, and goat anti-mouse IgM-Alexa Fluor[®] 488 conjugate were purchased from ThermoFisher Scientific. Pronase E. monoclonal anti-CD15 (Lewis x, Le^x) antibody and other chemicals were purchased from Sigma. They were used without further purification. Biotinylated plant lectins were purchased from Vector Laboratories. Other enzymes including sialidase BiNanH2 from Bifidobacterium longum subsp. infantis ATCC15697,¹ CMP-sialic acid synthetase from *Neisseria meningitidis* (NmCSS),² double mutant E271F/R313Y of *Pasteurella multocida* α 2–3-sialyltransferase 1 (PmST1 E271F/R313Y),³ Photobacterium damselae α 2–6-sialyltransferase (Pd2,6ST),⁴ *Campylobacter jejuni* sialyltransferase (CjCstII, serves as an α 2–8-sialyltransferase in this work),⁵ β1–3-N-acetylglucosaminyltransferase from N. meningitides (NmLgtA),⁶ β1–4galactosyltransferase from N. meningitides (NmLgtB),⁷ bovine α 1–3-galactosyltransferase $(B\alpha 1, 3GalT)$,⁸ and C-terminal 66 amino acids truncated $\alpha 1-3$ -fucosyltransferase from Helicobacter pylori (Hpa1,3FT)^{9,10} were expressed and purified as previously described. Enzymes were then desalted against 50 mM Tris-HCl, and 10% glycerol, and stored at -20 °C for long term use. Sugar nucleotides uridine 5'-diphospho-galactose (UDP-Gal),¹¹ UDP-Nacetylglucosamine (UDP-GlcNAc)¹² and guanosine 5'-diphospho-L-fucose (GDP-Fuc)¹² were prepared as described previously.

II. General methods for glycan preparation

A) Preparation of sialylglycopeptide (SGP)

SGP was isolated from fresh chicken egg yolk by the method reported in Ref. 13.

B) Preparation of the core *N*-glycan

The core N-glycan was prepared by sequential digestion of SGP with pronase E and sialidase.

i. Digestion of SGP by pronase E

SGP (5 mg) in Tris-HCl (50 mM, pH 8.8) was digested by pronase E (5 mg) at 37 °C for 2 days until no residual SGP was detected by HPLC-HILIC-ELSD. The reaction was terminated by boiling for 5 min. Semi-praparative Waters XBridge BEH amide column (130 Å, 5 μ m, 10 mm × 250 mm) was applied for purification. A gradient condition is solvent A: ammonium formate (100 mM, pH 3.4); solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65–50% within 25 min.

The peak corresponding to **BA-01** was pooled and lyophilized twice to remove ammonium formate. **BA-01** (3.5 mg) was obtained as a white powder.



Fig. S1 HILIC-UV purification of **BA-01**. Waters XBridge BEH amide column was used (130 Å, 5 μ m, 10 mm × 250 mm) under a gradient running condition (solvent A: ammonium formate (100 mM, pH 3.4); solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65–50% within 25 min).

ii. Sequential digestion of SGP by pronase E and sialidase

SGP (100 mg) in Tris-HCl (50 mM, pH 8.8) was digested by 100 mg pronase E at 37 °C for 2 days until no SGP could be detected by HPLC-HILIC-ELSD. The pH was adjusted to 8.0 before sialidase BiNanH2 (5 mg) was added, and reaction was incubated at 37 °C overnight. Semi-praparative Waters XBridge BEH amide column (130 Å, 5 μ m, 10 mm × 250 mm) was applied for purification. A gradient condition is solvent A: ammonium formate (100 mM, pH 3.4); solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65–50% within 25 min. The peak corresponding to **BA-02** was pooled and lyophilized twice to remove ammonium formate. **BA-02** (54 mg) was obtained as a white powder.



Fig. S2 HILIC-UV purification of **BA-02**. Waters XBridge BEH amide column was used (130 Å, 5 μ m, 10 mm × 250 mm) under a gradient running condition (solvent A: ammonium formate (100 mM, pH 3.4); solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65–50% within 25 min).

C) β1–3-GlcNAcylation catalyzed by NmLgtA

Reaction mixtures contained Tris-HCl (50 mM, pH 8.0), an acceptor glycan (4 mM), UDP-GlcNAc (8 mM), MnCl₂ (5 mM), and varying amounts of NmLgtA. FastAP (1 U/200 μ L) was also added to digest the reaction byproduct UDP to drive reaction forward. Reactions were incubated at 37 °C for 2 days, and were monitored by MALDI-TOF. After all acceptor was converted, the reaction was quenched by boiling for 5 min, followed by concentration using a vacufuge concentrator. HPLC-A_{210 nm} was then used to purify target glycans using a semi-preparative amide column (130 Å, 5 μ m, 10 mm × 250 mm).



Fig. S3 HILIC-UV purification of **BA-02'** (product of LgtA reaction with **BA-02** as acceptor). Waters XBridge BEH amide column was used (130 Å, 5 μ m, 10 mm × 250 mm) under a gradient running condition (solvent A: ammonium formate (100 mM, pH 3.4); solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65–50% within 25 min).

D) β 1–4-Galactosylation catalyzed by NmLgtB

Reaction mixtures contained Tris-HCl (50 mM, pH 8.0), an acceptor glycan (4 mM), UDP-Gal (8 mM), MnCl₂ (5 mM), and varying amounts of NmLgtB. FastAP (1 U/200 μ L) was also added to digest the reaction byproduct UDP to drive reaction forward. Reactions were incubated at 37 °C overnight, and were monitored by MALDI-TOF. After all acceptor was converted, the reaction was quenched by boiling for 5 min, followed by concentration using a vacufuge concentrator. HPLC-A_{210 nm} was then used to purify target glycans using a semi-preparative amide column (130 Å, 5 μ m, 10 mm × 250 mm).



Fig. S4 HILIC-UV purification of **BA-25**. Waters XBridge BEH amide column was used (130 Å, 5 μ m, 10 mm × 250 mm) under a gradient running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 4 mL/min; B%: 70-40% within 35 min).

E) α 1–3-Galactosylation catalyzed by B α 1,3GalT

Reaction mixtures contained Tris-HCl (50 mM pH 8.0), 4 mM acceptor glycans, UDP-Gal (8 mM), MnCl₂ (5 mM), and varying amounts of B α 1,3GalT. FastAP (1 U/200 μ L) was also added to digest the reaction byproduct UDP to drive reaction forward. Reactions were incubated at 37 °C overnight, and were monitored by MALDI-TOF. After all acceptor was converted, the reaction was quenched by boiling for 5 min, followed by concentration using a vacufuge concentrator. HPLC-A_{210nm} was then used to purify target glycans using a semi-preparative amide column (130 Å, 5 μ m, 10 mm × 250 mm).



Fig. S5 HILIC-UV purification of **BA-27**. Waters XBridge BEH amide column was used (130 Å, 5 μ m, 10 mm × 250 mm) under a gradient running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 4 mL/min; B%: 70-40% within 35 min).

F) α 1–3-Fucosylation catalyzed by Hp α 1,3FT

Reaction mixtures contained Tris-HCl (50 mM, pH 8.0), acceptor glycans (4 mM), GDP-Fuc (8 mM), MnCl₂ (5 mM), and varying amounts of Hp α 1,3FT. FastAP (1 U/200 µL) was also added to digest the reaction byproduct GDP to drive reaction forward. Reactions incubated at 37 °C overnight, and monitored by MALDI-TOF. After all acceptor was converted, the reaction was quenched by boiling for 5 min, followed by concentration using a vacufuge concentrator. HPLC-A_{210nm} was then used to purify target glycans using a semi-preparative amide column (130 Å, 5 µm, 10 mm × 250 mm).



Fig. S6 HILIC-UV purification of **BA-34**. Waters XBridge BEH amide column was used (130 Å, 5 μ m, 10 mm × 250 mm) under a gradient running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 4 mL/min; B%: 60-30% within 35 min).

G) α 2–3-Sialylation catalyzed by PmST1 E271F/R313Y

Reaction mixtures contained Tris-HCl (100 mM, pH 8.0), acceptor glycans (4 mM), CTP (8 mM), Neu5Ac/Neu5Gc (8 mM), MgCl₂ (5 mM), NmCSS (5 μ g/mL), and PmST1 E271F/R313Y (2 μ g/mL). Reactions were incubated at 37 °C for 45 min and quenched by boiling for 5 min, followed by concentration using a vacufuge concentrator. HPLC-A_{210nm} was then used to purify target glycans using a semi-preparative amide column (130 Å, 5 μ m, 10 mm × 250 mm).



Table S1 Acceptor substrate specificity of PmST1.

a. The percentage conversion is determined from HPLC-HILIC-ELSD data.

b. Not detected.



Fig. S7 HILIC-UV purification of **BA-19**. Waters XBridge BEH amide column was used (130 Å, 5 μ m, 10 mm × 250 mm) under a gradient running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 4 mL/min; B%: 57-47% within 25 min).

H) α 2–6-Sialylation catalyzed by Pd2,6ST

Reaction mixtures contained Tris-HCl (100 mM, pH 8.0), acceptor glycans (4 mM), CTP (8 mM), Neu5Ac/Neu5Gc (8 mM), MgCl₂ (5 mM), NmCSS (5 μ g/mL), and Pd2,6ST (5 μ g/mL). Reactions were incubated at 37 °C overnight and quenched by boiling for 5 min, followed by concentration using a vacufuge concentrator. HPLC-A_{210nm} was then used to purify target glycans using a semi-preparative amide column (130 Å, 5 μ m, 10 mm × 250 mm).



Fig. S8 HILIC-UV purification of **BA-03**. Waters XBridge BEH amide column was used (130 Å, 5 μ m, 10 mm × 250 mm) under a gradient running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 4 mL/min; B%: 65-50% within 25 min).

Scheme S1 Synthetic scheme for BA-23.



I) α 2–8-Sialylation catalyzed by CjCstII

Reaction mixtures contained Tris-HCl (100 mM, pH 8.0), acceptor glycans (4 mM), CTP (8 mM), Neu5Ac/Neu5Gc (8 mM), MgCl₂ (5 mM), NmCSS (5 μ g/mL), and CjCstII (2 μ g/mL). Reactions were incubated at 37 °C for 45 min and quenched by boiling for 5 min, followed by concentration using a vacufuge concentrator. HPLC-A_{210nm} was then used to purify target glycans using a semi-preparative amide column (130 Å, 5 μ m, 10 mm × 250 mm).

Table S2 C	Conversion	percentage	of reactions	catalyzed by	NmCSS	and CjCstII.
------------	------------	------------	--------------	--------------	-------	--------------

Acceptor	Donor	Product	Yield (%) ^a	Yield (%) ^a	Yield (%) ^a	Yield (%) ^a
		(2SA)	(0SA)	(1SA)	(2SA)	(3SA)
BA-01	CMP-Neu5Ac	BA-09	0	4	82	14
	CMP-Neu5Gc	BA-10	2	22	76	0
BA-03	CMP-Neu5Ac	BA-11	0	30	70	0
	CMP-Neu5Gc	BA-12	19	63	18	0
BA-04	CMP-Neu5Ac	BA-13	0	12	82	6
	CMP-Neu5Gc	BA-14	1	19	80	0
BA-05	CMP-Neu5Ac	BA-15	3	52	45	0
	CMP-Neu5Gc	BA-16	11	63	25	0

a. The percentage yield is calculated from HPLC-HILIC-ELSD data.



Fig. S9 HILIC-UV purification of **BA-13**. Waters XBridge BEH amide column was used (130 Å, 5 μ m, 10 mm × 250 mm) under a gradient running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 4 mL/min; B%: 60-45% within 35 min).

J) Summary of one-pot enzymatic extension of glycans

The sequences of one-pot enzymatic extension for glycan synthesis are summarized in Table S3.

Acceptor	Donor and Enzyme	Product	Yield
BA-02	с	BA-06	>99%
	d	BA-07	>99%
	d+c	BA-08	>99%
	a+b	BA-24	>99%
	a+b+a+b	BA-25	>99%
	a+b+d	BA-26	>99%
	a+b+a+b+d	BA-27	>99%
	a+c+b	BA-28	>99%
	a+b+c	BA-30	>99%
	a+c+b+d	BA-31	>99%
	a+b+c+d	BA-32	>99%
	a+b+a+c+b	BA-33	>99%
	a+b+a+b+c	BA-34	>99%
	a+b+a+c+b+d	BA-35	>99%
	a+b+a+b+c+d	BA-36	>99%

Table S3 Sequential one-pot enzymatic extension of glycans.

(a) UDP-GlcNAc, Mn^{2+} and NmLgtA; (b) UDP-Gal, Mn^{2+} and NmLgtB; (c) GDP-Fuc, Mn^{2+} and Hp α 1,3FT; (d) UDP-Gal, Mn^{2+} and B α 1,3GalT. The plus sign denotes the subsequent reactions were performed without purification of the product from the previous reaction.

III. General methods for HPLC-HILIC-UV purification of N-glycans

A) General methods for HILIC-UV210 purification of N-glycans

1) BA-01, BA-02, BA-03, BA-04, BA-05, BA-06, BA-07.

<u>Column</u>: Waters XBridge BEH amide column, 130 Å, 5 μ m, 10 mm \times 250 mm Solvent A: 100 mM ammonium formate, pH 3.4

Solvent B: Acetonitrile

Temperature: 40 °C

Gradient elution:	Time (min)	B%	Flow rate (mL/min)
	0	65	4
	25	50	4
	26	0	2
	27	0	2
	28	65	4
	30	65	4

Monitor: A_{210nm}

2) BA-08, BA-17, BA-18, BA-24, BA-25, BA-26, BA-27, BA-28, BA-29, BA-30, BA-31, BA-32, BA-33, BA-34.

<u>Column</u>: Waters XBridge BEH amide column, 130 Å, 5 μ m, 10 mm \times 250 mm

Solvent A: 100 mM ammonium formate, pH 3.4

Solvent B: Acetonitrile

Temperature: 40 °C

Gradient elution:	Time (min)	B%	Flow rate (mL/min)
	0	70	4
	35	40	4
	36	0	2
	37	0	2
	38	70	4
	45	70	4

Monitor: A_{210nm}

3) BA-09, BA-10, BA-11, BA-12, BA-13, BA-14, BA-15, BA-16.

<u>Column</u>: Waters XBridge BEH amide column, 130 Å, 5 μ m, 10 mm \times 250 mm Solvent A: 100 mM ammonium formate, pH 3.4

Solvent B: Acetonitrile

Temperature: 40 °C

Gradient elution:	Time (min)	B%	Flow rate (mL/min)
	0	60	4
	35	45	4
	36	0	2
	37	0	2
	38	60	4
	45	60	4

Monitor: A_{210nm}

4) BA-19, BA-20, BA-21, BA-22, BA-23.

<u>Column</u>: Waters XBridge BEH amide column, 130 Å, 5 μ m, 10 mm \times 250 mm Solvent A: 100 mM ammonium formate, pH 3.4

Solvent B: Acetonitrile

Temperature: 40 °C Gradient elution:

dient elution:	Time (min)	B%	Flow rate (mL/min)
	0	57	4
	35	47	4
	36	0	2
	37	0	2
	38	57	4
	45	57	4

Monitor: A_{210nm}

5) **BA-35**, **BA-36**.

<u>Column</u>: Waters XBridge BEH amide column, 130 Å, 5 μ m, 10 mm \times 250 mm Solvent A: 100 mM ammonium formate, pH 3.4

Solvent B: Acetonitrile

Temperature: 40 °C

Gradient elution:	Time (min)	B%	Flow rate (mL/min)
	0	60	4
	35	30	4
	36	0	2
	37	0	2
	38	70	4
	45	70	4

Monitor: A_{210nm}

B) General methods for HILIC-ELSD analysis of N-glycans

<u>Column</u>: Waters XBridge BEH amide column, 130 Å, 5 μ m, 4.6 mm \times 250 mm Solvent A: 100 mM ammonium formate, pH 3.4

Solvent B: Acetonitrile

Temperature: 40 °C

Gradient elution:	Time (min)	B%	Flow rate (mL/min)
	0	60	1
	35	30	1
	36	0	0.5
	37	0	0.5
	38	60	1
	45	60	1

Monitor: Evaporative light scattering detector, 60 °C (Shimadzu ELSD-LTII)

IV. General methods for mass spectrometry analysis

A) ESI-MS analysis of N-glycans

In this study, HPLC-MS experiments were performed on an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 high performance liquid chromatography system (Thermo Fisher). Samples were transmitted into MS with a silica column. LTQ-Orbitrap Elite mass spectrometer was operated in the data dependent mode. A full-scan survey MS experiment (m/z range from 375 to 1600; automatic gain control target, 1,000,000 ions; resolution at 400 m/z, 240,000; maximum ion accumulation time, 200 ms) was acquired by the Orbitrap mass spectrometer.

B) Method of MALDI-TOF MS analyses

MALDI-TOF MS analyses were performed on UltrafleXtreme MALDI TOF/TOF Mass Spectrometer (Bruker). Scan range of MS¹ was set according to the molecular weight of *N*glycans, and reflector mode was used for *N*-glycan analysis. Mass spectra were obtained in both positive and negative extraction mode with the following voltage settings: ion source 1 (19.0 kV), ion source 2 (15.9 kV), and lens (9.3 kV). The reflector voltage was set to 20 kV. The laser was pulsed at 7 Hz and the pulsed ion extraction time was set at 400 ns. The laser power was kept in the range of 25–40%.

V. General methods for glycan microarray assay

The glycans were printed on N-hydroxysuccinimide (NHS)-derivatized slides, each in replicates of 6 in a subarray, and 8 subarrays were printed on each slide. Contact printing was performed using 2470 Arrayer (Aushon Biosystems). All glycans were prepared at a concentration of 100 µM in phosphate buffer (100 mM sodium phosphate buffer, pH 8.5). The slides were fitted with 8-chamber adapter to separate the subarray into individual well for assay. Before assay, slides were rehydrated for 5 min in TSMW buffer (20 mM Tris-HCl, 150 mM NaCl, 0.2 mM CaCl₂, and 0.2 mM MgCl₂, 0.05% Tween). And then the analysis was performed for plant lectins, antibodies, and viruses as previously described.^{14,15} Eight subarrays were assayed with *Maackia* amurensis lectin I (MAL-I, binds NeuAca2–3-Galβ1–4GlcNAc, 10 µg/mL),¹⁶ Sambucus nigra lectin (SNA, binds NeuAcα2–6Galβ1–4GlcNAc, 10 µg/mL),¹⁷ Erythrina cristagalli lectin (ECL, binds Galβ1–4GlcNAc, 10 μg/mL),¹⁸ B subunit of Griffonia simplicifolia lectin I (GSL-I-B₄, binds α-Gal, 10 µg/mL),¹⁹ and wheat germ agglutinin (WGA, binds GlcNAc and sialic acids, 0.5 μg/mL, 2 μg/mL, 5 μg/mL, and 10 μg/mL).^{20,21} The biotinylated lectins were detected by Cy5streptavidin (1 µg/mL). Two subarrays were assayed with anti-CD15 antibody (binds Le^x epitope, 5 μ g/mL) and anti-CD15s antibody (binds sLe^x epitope, 20 μ g/mL), respectively. The primary antibodies were then bound by goat anti-mouse IgM-Alexa Fluor[®] 488 conjugate (5 µg/mL). Three subarrays were assayed with three influenza A viruses, including swine, avian and human vaccine strains.¹⁵ All viruses were labeled with Alexa Fluor 488 as previously described,^{15,22} and were incubated on the slide at 4 °C for 1 hour. The slides were scanned with a microarray scanner (InnoScan 1100 AL).

VI. HPLC profiles, MS and NMR data of purified N-glycans



HILIC-ELSD, $T_R = 21.034$ min.



ESI-MS, calculated 2337.9003; found [M+3H]³⁺ 780.2872, [M+2H]²⁺ 1169.9280.



¹**H** NMR (D₂O, 500 MHz): δ 5.14 (s, 1 H, Man4 H-1), 5.08 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4' H-1), 4.78 (s, 1 H, Man3 H-1), 4.60-4.63 (m, 3 H, GlcNAc 2 H-1, GlcNAc5 H-1, GlcNAc5' H-1), 4.45 (d, J = 7.3 Hz, 2 H, Gal6 H-1, Gal6' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.21 (brs, 1 H, Man4 H-2), 4.12 (brs, 1 H, Man4' H-2), 3.50-4.02 (m, 66 H), 2.94 (dd, J = 17.3, 4.2 Hz, 1 H, Asn-βCH₂), 2.87 (d, J = 17.3, 6.9 Hz, 1 H, Asn-βCH₂), 2.65-2.69 (m, 2 H, Neu5Ac H-3eq), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, 2 Ac), 2.04 (s, 6 H, 2 Ac), 2.02 (s, 3 H, Ac), 1.73 (t, J = 12.2 Hz, 2 H, Neu5Ac H-3ax).



HILIC-ELSD, $T_R = 19.076$ min.



MALDI-MS, calculated 1755.7094; found [M+Na]⁺ 1777.631, [M+K]⁺ 1793.619.



¹**H** NMR (D₂O, 500 MHz): δ5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 4.97 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.66 (d, J = 7.8 Hz, 1 H, GlcNAc 2 H-1), 4.62 (d, J = 7.8 Hz, 2 H, GlcNAc5 H-1, GlcNAc5' H-1), 4.51 (d, J = 7.8 Hz, 1 H, Gal6 H-1), 4.50 (d, J = 7.8 Hz, 1 Gal6' H-1), 4.29 (d, J = 1.8 Hz, 1 H, Man3 H-2), 4.23 (d, J = 1.7 Hz, 1 H, Man4 H-2), 4.15 (d, J = 1.8 Hz, 1 H, Man4' H-2), 3.51-4.04 (m, 52 H), 2.98 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH₂), 2.90 (d, J = 17.2, 6.8 Hz, 1 H, Asn-βCH₂), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac).



HILIC-ELSD, $T_R = 22.080$ min.



ESI-MS, calculated 2369.8901; found [M+3H]³⁺ 790.9512, [M+2H]²⁺ 1185.9225.



¹**H** NMR (D₂O, 500 MHz): δ 5.18 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.99 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.46-4.66 (m, 3 H, GlcNAc 2 H-1, GlcNAc5 H-1, GlcNAc5' H-1), 4.50 (d, J = 7.9 Hz, 1 H, Gal6 H-1), 4.49 (d, J = 7.8 Hz, 1 H, Gal6' H-1), 4.30 (s, 1 H, Man3 H-2), 4.24 (d, J = 2.2 Hz, 1 H, Man4 H-2), 4.16 (brs, 4 H, Man4' H-2), 3.52-4.06 (m, 70 H), 2.98 (dd, J = 17.3, 4.2 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 6.9 Hz, 1 H, Asn-βCH₂), 2.71-2.75 (m, 2 H, Neu5Gc H-3eq), 2.16 (s, 3 H, Ac), 2.12 (s, 3 H, Ac), 2.11 (s, 3 H, Ac), 2.06 (s, 3 H, Ac), 1.78 (t, J = 12.3 Hz, 2 H, Neu5Gc H-3ax).



HILIC-ELSD, $T_R = 19.947$ min.



ESI-MS, calculated 2337.9003; found [M+3H]³⁺ 780.2874, [M+2H]²⁺ 1169.9278.



¹**H** NMR (D₂O, 500 MHz): δ5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 4.97 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.66 (d, J = 7.9 Hz, 1 H, GlcNAc1 H-1), 4.58-4.62 (m, 4 H, GlcNAc5 H-1, GlcNAc5' H-1, Gal6 H-1, Gal6' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.23 (d, J = 1.9 Hz, 1 H, Man4 H-2), 4.15-4.16 (m, 3 H), 3.51-4.04 (m, 64 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH₂), 2.91 (dd, J = 17.3, 6.9 Hz, 1 H, Asn-βCH₂), 2.80 (dd, J = 12.4, 4.3 Hz, 2 H, Neu5Ac H-3eq), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 3 H, 2 Ac), 2.06 (s, 3 H, Ac), 1.84 (t, J = 12.4 Hz, 2 H, Neu5Ac H-3ax).



HILIC-ELSD, $T_R = 21.148$ min.



ESI-MS, calculated 2369.8901; found [M+3H]³⁺ 790.9506, [M+2H]²⁺ 1185.9227.



¹**H** NMR (D₂O, 500 MHz): δ 5.14 (s, 1 H, Man4 H-1), 5.07 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4' H-1), 4.78 (s, 1 H, Man3 H-1), 4.59-4.62 (m, 3 H, GlcNAc1 H-1, GlcNAc5 H-1, GlcNAc5' H-1), 4.45 (d, J = 7.4 Hz, 2 H, Gal6 H-1, Gal6' H-1), 4.26 (brs, 1 H, Man3 H-2), 4.20 (brs, 1 H, Man4 H-2), 4.12 (brs, 4 H), 3.50-4.03 (m, 67 H), 2.94 (dd, J = 17.3, 4.1 Hz, 1 H, Asn-βCH₂), 2.87 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH₂), 2.66-2.72 (m, 2 H, Neu5Gc H-3eq), 2.09 (s, 3 H, Ac), 2.08 (s, 6 H, 2 Ac), 2.02 (s, 3 H, Ac), 1.75 (t, J = 12.2 Hz, 2 H, Neu5Gc H-3ax).



HILIC-ELSD, $T_R = 20.965$ min.



Intens. [a.u.] 2069.837 0 -m/z

MALDI-MS, calculated 2047.8253; found [M+Na]⁺ 2069.837, [M+K]⁺ 2085.819.

¹**H** NMR (D₂O, 500 MHz): δ 5.17 (d, J = 3.4 Hz, 1 H, Fuc H-1), 5.16 (d, J = 3.5 Hz, 1 H, Fuc H-1), 5.14 (s, 1 H, Man4 H-1), 5.10 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4' H-1), 4.85-4.88 (m, 2 H, Man3 H-1, GlcNAc1 H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc5 H-1), 4.62 (d, J = 8.1 Hz, 1 H, GlcNAc5' H-1), 4.49 (d, J = 7.7 Hz, 1 H, Gal6 H-1), 4.48 (d, J = 7.6 Hz, 1 H, Gal6' H-1), 4.29 (brs, 1 H), 4.22 (d, J = 2.0 Hz, 1 H), 4.14 (d, J = 2.2 Hz, 1 H), 3.50-4.04 (m, 60 H), 2.96 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH₂), 2.89 (dd, J = 17.2, 6.9 Hz, 1 H, Asn-βCH₂), 2.12 (s, 3 H, Ac), 2.08 (s, 6 H, 2 Ac), 2.06 (s, 3 H, Ac), 1.22 (d, J = 6.4 Hz, 3 H, Fuc CH₃).



HILIC-ELSD, $T_R = 20.877$ min.



MALDI-MS, calculated 2079.8151; found [M+Na]⁺ 2101.899, [M+K]⁺ 2117.880.



¹**H** NMR (D₂O, 500 MHz): δ 5.12 (s, 1 H, Man4 H-1), 5.08 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 4.93 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.69 (d, J = 8.4 Hz, 2 H, GlcNAc1 H-1, GlcNAc5 H-1), 4.62 (d, J = 7.9 Hz, 1 H,GlcNAc5' H-1), 4.58 (d, J = 7.6 Hz, 2 H, Gal6 H-1, Gal6' H-1), 4.47 (d, J = 7.5 Hz, 1 H, Gal7 H-1), 4.46 (d, J = 7.6 Hz, 1 H, Gal7' H-1), 4.26 (brs, 1 H, Man3 H-2), 4.19 (brs, 1 H, Man4 H-2), 4.16 (brs, 2 H), 4.11 (brs, 1 H), 3.46-4.00 (m, 61 H), 2.94 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH₂), 2.87 (dd, J = 17.2, 6.8 Hz, 1 H, Asn-βCH₂), 2.08 (s, 3 H, Ac), 2.05 (s, 6 H, 2 Ac), 2.02 (s, 3 H, Ac).



HILIC-ELSD, $T_R = 22.716$ min.



Intens. [a.u.] 0001 2393.808 m/z

MALDI-MS, calculated 2371.9309; found [M+Na]⁺ 2393.808, [M+K]⁺ 2409.785.

¹**H** NMR (D₂O, 500 MHz): δ5.18 (d, J = 3.5 Hz, 2 H, Fuc H-1), 5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4' H-1), 4.85-4.87 (m, 2 H, GlcNAc2 H-1, GlcNAc5 H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.62-4.66 (m, 3 H, GlcNAc5' H-1, Gal6 H-1, Gal6' H-1), 4.56 (d, J = 7.7 Hz, 1 H, Gal7 H-1), 4.55 (d, J = 7.7 Hz, 1 H, Gal7 H-1), 4.29 (brs, 1 H, Man3 H-2), 4.20-4.24 (m, 5 H), 4.14 (d, J = 2.3 Hz, 1 H), 3.50-4.06 (m, 68 H), 2.98 (dd, J = 17.2, 4.4 Hz, 1 H, Asn-βCH₂), 2.91 (dd, J = 17.2, 6.8 Hz, 1 H, Asn-βCH₂), 2.12 (s, 3 H, Ac), 2.09 (s, 6 H, 2 Ac), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 1.23 (d, J = 6.3 Hz, 3 H, Fuc CH₃), 1.22 (d, J = 6.3 Hz, 3 H, Fuc CH₃).



HILIC-ELSD, $T_R = 22.309$ min.



ESI-MS, calculated 2920.0911; found [M+3H]³⁺ 974.3523, [M+2H]²⁺ 1461.0229.



¹**H** NMR (D₂O, 500 MHz): δ 5.17 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 5.00 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.64-4.67 (m, 3 H, GlcNAc2 H-1, GlcNAc5 H-1, GlcNAc5' H-1), 4.48 (d, J = 7.6 Hz, 2 H, Gal6 H-1, Gla6' H-1), 4.30 (brs, 1 H, Man3 H-2), 4.20-4.24 (m, 3 H), 4.14-4.16 (m, 3 H), 3.54-4.03 (m, 76 H), 2.98 (dd, J = 17.3, 4.2 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 7.0 Hz, 1 H, Asn-βCH₂), 2.82 (dd, J = 12.3, 4.4 Hz, 2 H, Neu5Ac H-3eq), 2.60-2.63 (m, 2 H, Neu5Ac H-3eq), 2.12 (s, 6 H, 2 Ac), 2.11 (s, 3 H, Ac), 2.10 (s, 6 H, 2 Ac), 2.07 (s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.79 (t, J = 12.3 Hz, 2 H, Neu5Ac H-3ax), 1.69 (t, J = 12.1 Hz, 2 H, Neu5Ac H-3ax).



HILIC-ELSD, $T_R = 23.342$ min.



ESI-MS, calculated 2952.0809; found [M+3H]³⁺ 985.0117, [M+2H]²⁺ 1477.0123.



¹**H** NMR (D₂O, 500 MHz): δ 5.17 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 5.00 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.64-4.67 (m, 3 H, GlcNAc2 H-1, GlcNAc5 H-1, GlcNAc5' H-1), 4.48 (d, J = 6.8 Hz, 2 H, Gal6 H-1, Gla6' H-1), 4.30 (brs, 1 H, Man3 H-2), 4.22-4.24 (m, 3 H), 4.14-4.16 (m, 3 H), 3.54-4.04 (m, 80 H), 2.98 (dd, J = 17.2, 4.1 Hz, 1 H, Asn-βCH₂), 2.93 (dd, J = 17.2, 7.0 Hz, 1 H, Asn-βCH₂), 2.84 (dd, J = 12.4, 4.5 Hz, 2 H, Neu5Ac H-3eq), 2.60-2.63 (m, 2 H, Neu5Gc H-3eq), 2.12 (s, 6 H, 2 Ac), 2.11 (s, 3 H, Ac), 2.10 (s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.80 (t, J = 12.4 Hz, 2 H, Neu5Ac H-3ax), 1.69 (t, J = 12.1 Hz, 2 H, Neu5Gc H-3ax).



HILIC-ELSD, $T_R = 22.883$ min.



ESI-MS, calculated 2952.0809; found [M+3H]³⁺ 985.0118, [M+2H]²⁺ 1477.0130.



¹**H** NMR (D₂O, 500 MHz): δ5.17 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 5.00 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.63-4.66 (m, 3 H, GlcNAc2 H-1, GlcNAc5 H-1, GlcNAc5' H-1), 4.48 (d, J = 7.6 Hz, 2 H, Gal6 H-1, Gla6' H-1), 4.31 (brs, 1 H, Man3 H-2), 4.22-4.25 (m, 4 H), 4.13-4.16 (m, 4 H), 3.54-4.04 (m, 78 H), 2.98 (dd, J = 17.3, 4.2 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 7.1 Hz, 1 H, Asn-βCH₂), 2.81 (dd, J = 12.5, 4.4 Hz, 2 H, Neu5Ac H-3eq), 2.61-2.64 (m, 2 H, Neu5Gc H-3eq), 2.13 (s, 6 H, 2 Ac), 2.12 (s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.06 (s, 3 H, Ac), 1.78 (t, J = 12.1 Hz, 2 H, Neu5Ac H-3ax), 1.71 (t, J = 12.3 Hz, 2 H, Neu5Gc H-3ax).



HILIC-ELSD, $T_R = 23.883$ min.



ESI-MS, calculated 2984.0708; found [M+3H]³⁺ 995.6749, [M+2H]²⁺ 1493.0063.



¹**H** NMR (D₂O, 500 MHz): δ 5.17 (s, 1 H, Man4 H-1), 5.11 (d, *J* = 9.7 Hz, 1 H, GlcNAc1 H-1), 5.00 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.64-4.67 (m, 3 H, GlcNAc2 H-1, GlcNAc5 H-1, GlcNAc5' H-1), 4.48 (d, *J* = 7.6 Hz, 2 H, Gal6 H-1, Gla6' H-1), 4.30 (brs, 1 H, Man3 H-2), 4.22-4.26 (m, 5 H), 4.12-4.16 (m, 5 H), 3.54-4.04 (m, 80 H), 2.98 (dd, *J* = 17.3, 4.0 Hz, 1 H, Asn-βCH₂), 2.90 (dd, *J* = 17.4, 7.1 Hz, 1 H, Asn-βCH₂), 2.83 (dd, *J* = 12.4, 4.5 Hz, 2 H, Neu5Gc H-3eq), 2.61-2.64 (m, 2 H, Neu5Gc H-3eq), 2.13 (s, 6 H, 2 Ac), 2.12 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 1.80 (t, *J* = 12.4 Hz, 2 H, Neu5Gc H-3ax), 1.71 (t, *J* = 12.1 Hz, 2 H, Neu5Gc H-3ax).



HILIC-ELSD, $T_R = 20.851$ min.



ESI-MS, calculated 2920.0911; found [M+3H]³⁺ 974.3483, [M+2H]²⁺ 1461.0177.



¹**H** NMR (D₂O, 500 MHz): δ5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.6 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc2 H-1), 4.48 (m, 4 H, , GlcNAc5 H-1, GlcNAc5' H-1, Gal6 H-1, Gla6' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.13-4.23 (m, 8 H), 3.54-4.04 (m, 74 H), 2.98 (dd, J = 17.4, 3.7 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.4, 6.8 Hz, 1 H, Asn-βCH₂), 2.81-2.83 (m, 2 H, Neu5Ac H-3eq), 2.71-2.73 (m, 2 H, Neu5Ac H-3eq), 2.12 (s, 3 H, Ac), 2.11 (s, 6 H, 2 Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.78 (t, J = 11.5 Hz, 4 H, Neu5Ac H-3ax).



HILIC-ELSD, $T_R = 21.858$ min.



ESI-MS, calculated 2952.0809; found [M+3H]³⁺ 985.0113, [M+2H]²⁺ 1477.0131.



¹**H** NMR (D₂O, 500 MHz): δ 5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc2 H-1), 4.57-4.62 (m, 4 H, GlcNAc5 H-1, GlcNAc5' H-1, Gal6 H-1, Gla6' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.12-4.23 (m, 10 H), 3.54-4.04 (m, 76 H), 2.98 (dd, J = 17.3, 4.0 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH₂), 2.83 (dd, J = 12.0, 3.9 Hz, 2 H, Neu5Ac H-3eq), 2.71-2.73 (m, 2 H, Neu5Gc H-3eq), 2.12 (s, 3 H, Ac), 2.11 (s, 6 H, 2 Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 1.75-1.82 (m, 4 H, Neu5Ac H-3ax, Neu5Gc H-3ax).



HILIC-ELSD, $T_R = 21.895$ min.



ESI-MS, calculated 2952.0809; found [M+3H]³⁺ 985.0113, [M+2H]²⁺ 1477.0136.



¹**H** NMR (D₂O, 500 MHz): δ5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.65 (d, J = 7.9 Hz, 1 H, GlcNAc2 H-1), 4.57-4.62 (m, 4 H, GlcNAc5 H-1, GlcNAc5' H-1, Gal6 H-1, Gla6' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.26 (brs, 1 H), 4.13-4.23 (m, 9 H), 3.54-4.06 (m, 76 H), 2.98 (dd, J = 17.3, 3.9 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 6.9 Hz, 1 H, Asn-βCH₂), 2.79-2.83 (m, 2 H, Neu5Ac H-3eq), 2.72-2.76 (m, 2 H, Neu5Gc H-3eq), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.75-1.80 (m, 4 H, Neu5Ac H-3ax).



HILIC-ELSD, $T_R = 22.941$ min.



ESI-MS, calculated 2984.0708; found [M+3H]³⁺ 995.6746, [M+2H]²⁺ 1493.0075.



¹**H** NMR (D₂O, 500 MHz): δ 5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.65 (d, J = 7.9 Hz, 1 H, GlcNAc2 H-1), 4.57-4.62 (m, 4 H, GlcNAc5 H-1, GlcNAc5' H-1, Gal6 H-1, Gla6' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.26 (brs, 1 H), 4.13-4.23 (m, 11 H), 3.54-4.06 (m, 78 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn- β CH₂), 2.90 (dd, J = 17.3, 7.1 Hz, 1 H, Asn- β CH₂), 2.83 (dd, J = 12.3, 4.4 Hz, 2 H, Neu5Gc H-3eq), 2.74 (dd, J = 12.8, 4.7 Hz, 2 H, Neu5Gc H-3eq), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 1.79 (t, J = 12.3 Hz, 4 H, Neu5Gc H-3ax).



HILIC-ELSD, $T_R = 21.476$ min.



ESI-MS, calculated 2630.0161; found [M+3H]³⁺ 877.6557, [M+2H]²⁺ 1315.9793.



¹**H** NMR (D₂O, 500 MHz): δ5.17 (d, J = 3.7 Hz, 1 H, Fuc H-1), 5.16 (d, J = 3.9 Hz, 1 H, Fuc H-1), 5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc2 H-1), 4.62 (d, J = 8.2 Hz, 2 H, GlcNAc5 H-1, GlcNAc5' H-1), 4.56 (d, J = 7.5 Hz, 1 H, Gal6 H-1), 4.55 (d, J = 7.5 Hz, 1 H, Gal6' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (brs, 1 H), 4.11-4.14 (m, 4 H), 3.50-4.04 (m, 71 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 6.9 Hz, 1 H, Asn-βCH₂), 2.80 (dd, J = 12.3, 4.2 Hz, 2 H, Neu5Ac H-3eq), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.84 (t, J = 12.0 Hz, 2 H, Neu5Ac H-3ax), 1.21 (d, J = 6.1 Hz, 3 H, Fuc CH₃), 1.20 (d, J = 6.2 Hz, 3 H, Fuc CH₃).



HILIC-ELSD, $T_R = 22.572$ min.



ESI-MS, calculated 2662.0059; found [M+3H]³⁺ 888.3190, [M+2H]²⁺ 1331.9748.



¹**H** NMR (D₂O, 500 MHz): δ 5.16 (d, J = 3.6 Hz, 1 H, Fuc H-1), 5.15 (d, J = 3.8 Hz, 1 H, Fuc H-1), 5.14 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4' H-1), 4.86 (t, J = 6.0 Hz, 1 H), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.65 (d, J = 7.6 Hz, 1 H, GlcNAc2 H-1), 4.62 (d, J = 7.8 Hz, 2 H, GlcNAc5 H-1, GlcNAc5' H-1), 4.56 (d, J = 7.7 Hz, 1 H, Gal6 H-1), 4.55 (d, J = 7.6 Hz, 1 H, Gal6' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (d, J = 2.1 Hz, 1 H), 4.12-4.16 (m, 5 H), 3.49-4.06 (m, 73 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 6.9 Hz, 1 H, Asn-βCH₂), 2.82 (dd, J = 12.3, 4.3 Hz, 2 H, Neu5Gc H-3eq), 2.12 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 3 H, Ac), 2.05 (s, 6 H, 2 Ac), 1.85 (t, J = 12.1 Hz, 2 H, Neu5Gc H-3ax), 1.21 (d, J = 6.2 Hz, 3 H, Fuc CH₃), 1.20 (d, J = 6.2 Hz, 3 H, Fuc CH₃).



HILIC-ELSD, $T_R = 21.703$ min.



ESI-MS, calculated 3068.1647; found [M+3H]³⁺ 1023.7105, [M+2H]²⁺ 1535.0579.



¹**H** NMR (D₂O, 500 MHz): δ5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 4.97 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 8.2 Hz, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.66 (d, J = 7.9 Hz, 1 H, GlcNAc5' H-1), 4.59-4.62 (m, 4 H, GlcNAc7 H-1, GlcNAc7' H-1, Gal6 H-1, Gal6' H-1), 4.50 (d, J = 7.6 Hz, 1 H, Gal8 H-1), 4.49 (d, J = 7.6 Hz, 1 H, Gal8' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.23 (brs, 1 H), 4.20 (brs, 2 H), 4.16 (d, J = 2.7 Hz, 1 H), 4.14 (d, J = 2.5 Hz, 2 H), 3.51-4.03 (m, 86 H), 2.98 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH₂), 2.91 (dd, J = 17.3, 6.9 Hz, 1 H, Asn-βCH₂), 2.80 (dd, J = 12.4, 4.5 Hz, 2 H, Neu5Ac H-3eq), 2.11 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 12 H, 4 Ac), 2.05 (s, 3 H, Ac), 1.84 (t, J = 12.4 Hz, 2 H, Neu5Ac H-3ax).



HILIC-ELSD, $T_R = 22.661$ min.



ESI-MS, calculated 3100.1545; found [M+3H]³⁺ 1034.3748, [M+2H]²⁺ 1551.0538.



¹**H** NMR (D₂O, 500 MHz): δ5.15 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.97 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 8.1 Hz, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc5' H-1), 4.59-4.62 (m, 4 H, GlcNAc7 H-1, GlcNAc7' H-1, Gal6 H-1, Gal6' H-1), 4.50 (d, J = 7.6 Hz, 1 H, Gal8 H-1), 4.49 (d, J = 7.6 Hz, 1 H, Gal8' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.23 (brs, 1 H), 4.20 (brs, 2 H), 4.13-4.18 (m, 5 H), 3.51-4.03 (m, 88 H), 2.98 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH₂), 2.91 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH₂), 2.81 (dd, J = 12.4, 4.5 Hz, 2 H, Neu5Ac H-3eq), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 12 H, 4 Ac), 2.05 (s, 3 H, Ac), 1.85 (t, J = 12.4 Hz, 2 H, Neu5Ac H-3ax).



HILIC-ELSD, $T_R = 23.996$ min.



ESI-MS, calculated 3650.3555; found [M+4H]⁴⁺ 913.5821, [M+3H]³⁺ 1217.7748.



¹**H** NMR (D₂O, 500 MHz): δ 5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.6 Hz, 1 H, GlcNAc1 H-1), 4.98 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 7.3 Hz, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.63-4.66 (m, 3 H, GlcNAc5' H-1, GlcNAc7 H-1, GlcNAc7' H-1), 4.45-4.50 (m, 4 H, Gal6 H-1, Gal6' H-1, Gal8 H-1, Gal8' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (brs, 1 H), 4.20 (brs, 2 H), 4.15 (m, 2 H), 3.51-4.05 (m, 101 H), 2.98 (dd, J = 17.2, 3.6 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 6.5 Hz, 1 H, Asn-βCH₂), 2.68-2.71 (dd, 4 H, Neu5Ac H-3eq), 2.11 (s, 3 H, Ac), 2.09 (s, 6 H, 2 Ac), 2.08 (s, 3 H, Ac), 2.06 (s, 12 H, 4 Ac), 2.04 (s, 3 H, Ac), 1.71-1.77 (m, 4 H, Neu5Ac H-3ax).



HILIC-ELSD, $T_R = 25.652$ min.



ESI-MS, calculated 3714.3352; found [M+4H]⁴⁺ 929.5767, [M+3H]³⁺ 1239.1026.



¹**H** NMR (D₂O, 500 MHz): δ 5.17 (s, 1 H, Man4 H-1), 5.11 (d, *J* = 9.8 Hz, 1 H, GlcNAc1 H-1), 4.98 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.75 (d, *J* = 7.6 Hz, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.63-4.66 (m, 3 H, GlcNAc5' H-1, GlcNAc7 H-1, GlcNAc7' H-1), 4.47-4.51 (m, 4 H, Gal6 H-1, Gal6' H-1, Gal8 H-1, Gal8' H-1), 4.30 (brs, 1 H, Man3 H-2), 4.21-4.23 (m, 4 H), 4.15-4.17 (m, 4 H), 3.54-4.03 (m, 106 H), 2.98 (dd, *J* = 17.3, 4.3 Hz, 1 H, Asn-βCH₂), 2.90 (dd, *J* = 17.3, 7.0 Hz, 1 H, Asn-βCH₂), 2.73 (dd, *J* = 12.3, 4.3 Hz, 4 H, Neu5Gc H-3eq), 2.12 (s, 3 H, Ac), 2.11 (s, 3 H, Ac), 2.10 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 1.74-1.80 (m, 4 H, Neu5Gc H-3ax).



HILIC-ELSD, $T_R = 23.283$ min.



ESI-MS, calculated 3650.3555; found [M+4H]⁴⁺ 913.5816, [M+3H]³⁺ 1217.7743.



¹**H** NMR (D₂O, 500 MHz): δ5.17 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.99 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.72 (d, J = 8.2 Hz, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.63-4.66 (m, 3 H, GlcNAc5' H-1, GlcNAc7 H-1, GlcNAc7' H-1), 4.59 (d, J = 7.8 Hz, 2 H, Gal6 H-1, Gal6' H-1), 4.46-4.48 (m, 2 H, Gal8 H-1, Gal8' H-1), 4.30 (brs, 1 H, Man3 H-2), 4.23 (d, J = 1.9 Hz, 1 H), 4.21 (brs, 2 H), 4.14-4.17 (m, 3 H), 3.51-4.04 (m, 100 H), 2.98 (dd, J = 17.2, 4.2 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 7.0 Hz, 1 H, Asn-βCH₂), 2.80 (dd, J = 12.5, 4.5 Hz, 2 H, Neu5Ac H-3eq), 2.68-2.72 (m, 2 H, Neu5Ac H-3eq), 2.12 (s, 3 H, Ac), 2.11 (s, 3 H, Ac), 2.10 (s, 3 H, Ac), 2.07 (s, 18 H, 6 Ac), 2.05 (s, 3 H, Ac), 1.84 (t, J = 12.5 Hz, 2 H, Neu5Ac H-3ax), 1.75 (t, J = 12.1 Hz, 2 H, Neu5Ac H-3ax).


HILIC-ELSD, $T_R = 21.225$ min.



MALDI-MS, calculated 2485.9738; found [M+Na]⁺ 2507.573, [M+K]⁺ 2523.541.



¹**H** NMR (D₂O, 500 MHz): δ 5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.97 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 8.3 Hz, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc5' H-1), 4.61 (d, J = 7.7 Hz, 2 H, GlcNAc7 H-1, GlcNAc7' H-1), 4.49-4.53 (m, 4 H, Gal6 H-1, Gal6' H-1, Gal8 H-1, Gal8' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (d, J = 2.1 Hz, 1 H), 4.20 (brs, 2 H), 4.14 (d, J = 2.3 Hz, 1 H), 3.51-4.03 (m, 74 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH₂), 2.80 (dd, J = 12.5, 4.5 Hz, 2 H, Neu5Ac H-3eq), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.06 (s, 3 H, Ac), 2.05 (s, 3 H, Ac).



HILIC-ELSD, $T_R = 22.644$ min.



MALDI-MS, calculated 3216.2382; found [M+Na]⁺ 3238.343, [M+K]⁺ 3254.335.



¹**H** NMR (D₂O, 500 MHz): δ 5.15 (s, 1 H, Man4 H-1), 5.11 (d, *J* = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.96 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, *J* = 8.2 Hz, 3 H, GlcNAc 2 H-1, GlcNAc5 H-1, GlcNAc5' H-1), 4.65 (d, *J* = 7.8 Hz, 1 H, GlcNAc7 H-1), 4.62 (d, *J* = 7.6 Hz, 2 H, GlcNAc7' H-1, GlcNAc8 H-1), 4.47-4.53 (m, 7 H, GlcNAc8' H-1, Gal6 H-1, Gal6' H-1, Gal8 H-1, Gal8' H-1, Gal10 H-1, Gal10' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (brs, 1 H), 4.19 (brs, 4 H), 4.14 (d, *J* = 1.8 Hz, 1 H), 3.51-4.04 (m, 96 H), 2.97 (dd, *J* = 17.2, 4.3 Hz, 1 H, Asn-βCH₂), 2.90 (dd, *J* = 17.3, 6.8 Hz, 1 H, Asn-βCH₂), 2.11 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 12 H, 4 Ac), 2.05 (s, 3 H, Ac).



HILIC-ELSD, $T_R = 22.564$ min.



MALDI-MS, calculated 2810.0795; found [M+Na]⁺ 2831.924, [M+K]⁺ 2847.912.



¹**H** NMR (D₂O, 500 MHz): *δ*5.19 (d, J = 3.7 Hz, Gal-9 H-1, Gal9' H-1), 5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.97 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 8.2 Hz, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc5' H-1), 4.58-4.63 (m, 4 H, GlcNAc7 H-1, GlcNAc7' H-1, Gal6 H-1, Gal6' H-1), 4.50 (d, J = 7.6 Hz, 1 H, Gal8 H-1), 4.49 (d, J = 7.5 Hz, 1 H, Gal8' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.20-4.24(m, 7 H), 4.14 (brs, 1 H), 4.05-4.06 (m, 2 H), 3.97-4.04 (m, 8 H), 3.69-3.91 (m, 60 H), 3.51-3.56 (m, 2 H), 2.98 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH₂), 2.10 (dd, J = 17.2, 4.3 Hz, 1 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac).



HILIC-ELSD, $T_R = 23.654$ min.



MALDI-MS, calculated 3540.3439; found [M+Na]⁺ 3562.375, [M+K]⁺ 3578.362.



¹**H** NMR (D₂O, 500 MHz): δ 5.18 (d, J = 3.7 Hz, Gal-11 H-1, Gal11' H-1), 5.16 (s, 1 H, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.97 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74-4.76 (m, 3 H, GlcNAc 2 H-1, GlcNAc5 H-1, GlcNAc5' H-1), 4.65 (d, J = 7.8 Hz, 1 H, GlcNAc7 H-1), 4.58-4.62 (m, 5 H, , GlcNAc7' H-1, GlcNAc9 H-1, GlcNAc9' H-1, Gal6 H-1, Gal6' H-1), 4.48-4.52 (m, 4 H, Gal8 H-1, Gal8' H-1, Gal10 H-1, Gal10' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.20-4.24(m, 8 H), 4.14 (d, J = 2.2 Hz, 1 H), 4.05-4.06 (m, 2 H), 3.50-4.03 (m, 103 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH₂), 2.12 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 12 H, 4 Ac), 2.05 (s, 3 H, Ac).



HILIC-ELSD, $T_R = 22.891$ min.



MALDI-MS, calculated 2778.0897; found [M+Na]⁺ 2799.728, [M+K]⁺ 2815.709.



¹**H** NMR (D₂O, 500 MHz): δ5.14-5.16 (m, 3 H, Fuc H-1, Man4 H-1), 5.10 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 8.0 Hz, GlcNAc 2 H-1), 4.62-4.66 (m, 3 H, GlcNAc5 H-1, GlcNAc5' H-1, GlcNAc7 H-1), 4.51-4.53 (m, 3 H, GlcNAc7' H-1, Gal6 H-1, Gal6' H-1), 4.47 (d, J = 7.6 Hz, 1 H, Gal8 H-1), 4.46 (d, J = 7.6 Hz, 1 H, Gal8' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (d, J = 2.3 Hz, 1 H), 4.14 (brs, 3 H), 3.50-4.04 (m, 81 H), 2.98 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.2, 6.8 Hz, 1 H, Asn-βCH₂), 2.12 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.06 (s, 9 H, 3 Ac), 2.05 (s, 3 H, Ac), 1.19 (d, J = 6.2 Hz, 3 H, Fuc CH₃), 1.18 (d, J = 6.2 Hz, 3 H, Fuc CH₃).



HILIC-ELSD, $T_R = 23.063$ min.



ESI-MS, calculated 3360.2805; found [M+3H]³⁺ 1121.0820.



¹**H** NMR (D₂O, 500 MHz): δ5.14-5.16 (m, 3 H, Fuc5 H-1, Fuc5' H-1, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4' H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 7.7 Hz, 1 H, GlcNAc 2 H-1), 4.59-4.66 (m, 5 H, , GlcNAc5 H-1, GlcNAc5' H-1, GlcNAc7 H-1, GlcNAc7' H-1, Gal6 H-1), 4.51 (d, J = 7.8 Hz, 1 H, Gal6' H-1), 4.47 (d, J = 7.3 Hz, 1 H, , Gal8 H-1), 4.46 (d, 1 H, Gal8' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (brs, 1 H), 4.16 (d, J = 2.6 Hz, 1 H), 4.14 (brs, 4 H), 3.50-4.06 (m, 94 H), 2.97 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH₂), 2.79 (dd, J = 12.4, 4.5 Hz, 2 H, Neu5Ac H-3eq), 2.11 (s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.06 (s, 12 H, 4 Ac), 2.05 (s, 3 H, Ac), 1.83 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3ax), 1.19 (d, J = 5.9 Hz, 3 H, Fuc CH₃), 1.18 (d, J = 5.9 Hz, 3 H, Fuc CH₃).



HILIC-ELSD, $T_R = 24.067$ min.



MALDI-MS, calculated 3070.2055; found [M+Na]⁺ 3091.861, [M+K]⁺ 3107.847.



¹**H** NMR (D₂O, 500 MHz): δ 5.18 (d, J = 3.7 Hz, 2 H, Fuc H-1), 5.16 (s, 1 H, Man4 H-1), 5.15 (d, J = 3.9 Hz, 2 H, Fuc H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4' H-1), 4.87 (d, J = 6.7 Hz, 1 H, GlcNAc 2 H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 8.0 Hz, GlcNAc5 H-1), 4.62-4.66 (m, 3 H, GlcNAc5' H-1, GlcNAc7 H-1, GlcNAc7' H-1), 4.50 (d, J = 7.8 Hz, 2 H, Gal6 H-1, Gal6' H-1), 4.47 (d, J = 7.5 Hz, 1 H, Gal8 H-1), 4.46 (d, J = 7.1 Hz, 1 H, Gal8' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (d, J = 1.9 Hz, 1 H), 4.14 (brs, 4 H), 3.50-4.04 (m, 80 H), 2.98 (dd, J = 17.3, 4.4 Hz, 1 H, Asn-βCH₂), 2.91 (dd, J = 17.2, 6.8 Hz, 1 H, Asn-βCH₂), 2.12 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.06 (s, 6 H, 2 Ac), 2.05 (s, 6 H, 2 Ac), 1.21 (d, J = 6.6 Hz, 6 H, 2 Fuc CH₃), 1.19 (d, J = 6.3 Hz, 3 H, Fuc CH3), 1.18 (d, J = 6.1 Hz, 3 H, Fuc CH₃).



HILIC-ELSD, $T_R = 24.016$ min.



Intens. [a.u.] 3123.988 m/z

MALDI-MS, calculated 3102.1953; found [M+Na]⁺ 3123.988, [M+K]⁺ 3139.978.

¹**H** NMR (D₂O, 500 MHz): δ 5.18 (d, J = 3.7 Hz, 2 H, Gal9 H-1, Gal9' H-1), 5.15 (s, 1 H, Man4 H-1), 5.14 (d, J = 3.7 Hz, 2 H, Fuc H-1), 5.10 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4' H-1), 4.84 (d, J = 6.8 Hz, 1 H, GlcNAc 2 H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 7.6 Hz, 1 H, GlcNAc5 H-1), 4.58-4.66 (m, 5 H, GlcNAc5' H-1, GlcNAc7 H-1, GlcNAc7' H-1, Gal6 H-1, Gal6' H-1), 4.47 (d, J = 7.2 Hz, 1 H, Gal8 H-1), 4.46 (d, J = 7.0 Hz, 1 H, Gal8' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.21-4.24 (m, 5 H), 4.13 (m, 3 H), 3.51-4.06 (m, 80 H), 2.98 (dd, J = 17.4, 4.1 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.4, 7.0 Hz, 1 H, Asn-βCH₂), 2.11 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.06(s, 6 H, 2 Ac), 2.05 (s, 3 H, Ac), 1.19 (d, J = 5.9 Hz, 3 H, Fuc CH₃), 1.18 (d, J = 6.0 Hz, 3 H, Fuc CH₃).



HILIC-ELSD, $T_R = 25.127$ min.



Intens. [a.u.] 000 <u>3416.2</u>01 200 100 0 1500 2000 2500 3000 3500 4000 m/z

MALDI-MS, calculated 3394.3111; found [M+Na]⁺ 3416.201, [M+K]⁺ 3432.191.

¹**H NMR** (D₂O, 500 MHz): δ 5.19 (d, J = 3.6 Hz, 4 H, Gal9 H-1, Gal9' H-1, Fuc7 H-1, Fuc7' H-1), 5.16 (s, 1 H, Man4 H-1), 5.15 (d, J = 3.7 Hz, 2 H, Fuc5 H-1, Fuc5' H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4' H-1), 4.87 (d, J = 6.8 Hz, 1 H, GlcNAc 2 H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.75 (d, J = 8.2 Hz, 1 H, GlcNAc5 H-1), 4.62-4.66 (m, 3 H, GlcNAc5' H-1, GlcNAc7 H-1, GlcNAc7' H-1), 4.58 (d, J = 7.7 Hz, 2 H, Gal6 H-1, Gal6' H-1), 4.45-4.48 (m, 2 H, Gal8 H-1, Gal8' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.20-4.25 (m, 5 H), 4.13 (brs, 3 H), 3.50-4.06 (m, 88 H), 2.98 (dd, J = 17.4, 4.4 Hz, 1 H, Asn- β CH₂), 2.91 (dd, J = 17.4, 6.8 Hz, 1 H, Asn- β CH₂), 2.12 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.06 (s, 12 H, 4 Ac), 1.22 (d, J = 6.5 Hz, 6 H, 6 H, Fuc CH₃), 1.20 (d, J = 5.9 Hz, 3 H, Fuc CH₃), 1.19 (d, J = 5.8 Hz, 3 H, Fuc CH₃).



HILIC-ELSD, $T_R = 25.084$ min.



MALDI-MS, calculated 3800.4699; found [M+Na]⁺ 3822.483, [M+K]⁺ 3838.475.

¹**H** NMR (D₂O, 500 MHz): δ 5.16 (brs, 5 H, Fuc7 H-1, Fuc7' H-1, Fuc5 H-1, Fuc5' H-1, Man4 H-1), 5.11 (d, J = 9.8 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4' H-1), 4.85 (d, J = 6.8 Hz, 1 H, GlcNAc 2 H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 8.0 Hz, 2 H, GlcNAc5 H-1, GlcNAc5' H-1), 4.62-4.66 (m, 3 H, GlcNAc7 H-1, GlcNAc7' H-1, GlcNAc9 H-1), 4.46-4.53 (m, 7 H, GlcNAc9' H-1, Gal6 H-1, Gal6' H-1, Gal8 H-1, Gal8' H-1, Gal10 H-1, Gal10' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (brs, 1 H), 4.13 (m, 8 H), 3.50-4.04 (m, 109 H), 2.97 (dd, J = 17.2, 3.3 Hz, 1 H, Asn-βCH₂), 2.91 (dd, J = 17.2, 6.6 Hz, 1 H, Asn-βCH₂), 2.12 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 9 H, 3 Ac), 2.05 (s, 9 H, Ac), 1.19 (d, J = 5.3 Hz, 12 H, 4 Fuc CH₃).



HILIC-ELSD, $T_R = 26.016$ min.





MALDI-MS, calculated 4092.5857; found [M+Na]⁺ 4114.752, [M+K]⁺ 4130.760.

¹**H** NMR (D₂O, 500 MHz): δ5.15-5.18 (m, 7 H, Fuc5 H-1, Fuc5' H-1, Fuc7 H-1, Fuc7' H-1, Fuc9 H-1, Fuc9' H-1, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4' H-1), 4.84-4.88 (m, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 8.2 Hz, 2 H, GlcNAc5' H-1, GlcNAc7 H-1), 4.62-4.66 (m, 3 H, GlcNAc7' H-1, GlcNAc9 H-1, GlcNAc9' H-1), 4.45-4.51 (m, 6 H, Gal6 H-1, Gal6' H-1, Gal8 H-1, Gal8' H-1, Gal10 H-1, Gal10' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22 (brs, 1 H), 4.14 (m, 7 H), 3.50-4.04 (m, 118 H), 2.98 (dd, J = 17.2, 4.3 Hz, 1 H, Asn-βCH₂), 2.91 (dd, J = 17.2, 6.7 Hz, 1 H, Asn-βCH₂), 2.12 (s, 3 H, Ac), 2.08 (s, 6 H, 2 Ac), 2.06 (s, 15 H, 5 Ac), 1.21 (d, J = 6.6 Hz, 6 H, 2 Fuc CH₃), 1.19 (d, J = 6.1 Hz, 12 H, 4 Fuc CH₃).



HILIC-ELSD, $T_R = 25.860$ min.



Intens. [a.u.] 4147.558 150 100 50 الملاط المخصاف المالية 0 2500 3000 3500 4500 1500 2000 4000 5000 m/z

MALDI-MS, calculated 4124.5755; found [M+Na]⁺ 4147.558, [M+K]⁺ 4163.586.

¹**H** NMR (D₂O, 500 MHz): *δ* 5.18 (d, J = 3.8 Hz, 2 H, Gal11 H-1, Gal11' H-1), 5.12-5.16 (m, 5 H, Fuc5 H-1, Fuc5' H-1, Fuc7 H-1, Fuc7' H-1, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4' H-1), 4.85 (d, J = 6.2 Hz, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.74 (d, J = 8.1 Hz, 2 H, GlcNAc5' H-1, GlcNAc7 H-1), 4.65 (d, J = 7.9 Hz, 1 H, GlcNAc7' H-1), 4.63 (d, J = 8.1 Hz, 1 H, GlcNAc9 H-1), 4.59 (d, J = 7.8 Hz, 1 H, GlcNAc9' H-1), 4.45-4.50 (m, 6 H, Gal6 H-1, Gal6' H-1, Gal8 H-1, Gal8' H-1, Gal10 H-1, Gal10' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22-4.24 (m, 5 H), 4.14 (brs, 5 H), 3.50-4.06 (m, 120 H), 2.98 (dd, J = 17.3, 4.3 Hz, 1 H, Asn-βCH₂), 2.90 (dd, J = 17.3, 6.8 Hz, 1 H, Asn-βCH₂), 2.12 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.07 (s, 9 H, 3 Ac), 2.05 (s, 9 H, 3 Ac), 1.19 (d, J = 6.1 Hz, 12 H, 4 Fuc CH₃).



HILIC-ELSD, $T_R = 26.784$ min.



MALDI-MS, calculated 4416.6913; found [M+Na]⁺ 4439.416, [M+K]⁺ 4455.475.



¹**H** NMR (D₂O, 500 MHz): δ5.15-5.19 (m, 9 H, Gal11 H-1, Gal11' H-1, Fuc5 H-1, Fuc5' H-1, Fuc7 H-1, Fuc7' H-1, Fuc9 H-1, Fuc9' H-1, Man4 H-1), 5.11 (d, J = 9.7 Hz, 1 H, GlcNAc1 H-1), 4.95 (s, 1 H, Man4' H-1), 4.84-4.87 (m, 2 H, GlcNAc 2 H-1, GlcNAc5 H-1), 4.81 (s, 1 H, overlap with D₂O, Man3 H-1), 4.75 (d, J = 8.0 Hz, 2 H, GlcNAc5' H-1, GlcNAc7 H-1), 4.62-4.66 (m, 2 H, GlcNAc7' H-1, GlcNAc9 H-1), 4.57 (d, J = 7.7 Hz, 2 H, GlcNAc9' H-1, Gal6 H-1), 4.46-4.49 (m, 5 H, Gal6' H-1, Gal8 H-1, Gal8' H-1, Gal10 H-1, Gal10' H-1), 4.29 (brs, 1 H, Man3 H-2), 4.22-4.25 (m, 5 H), 4.14 (brs, 5 H), 3.50-4.06 (m, 128 H), 2.98 (dd, J = 17.4, 4.2 Hz, 1 H, Asn-βCH₂), 2.91 (dd, J = 17.4, 6.8 Hz, 1 H, Asn-βCH₂), 2.12 (s, 3 H, Ac), 2.08 (s, 6 H, 2 Ac), 2.06 (s, 15 H, 5 Ac), 1.19 (d, J = 6.0 Hz, 18 H, 6 Fuc CH₃).

VI. NMR spectra of purified *N*-glycans





S51



S52





S54




























































¹H NMR of BA-26









¹H NMR of BA-29























¹H NMR of BA-35







VII. References

- 1. D. A. Sela, Y. Li, L. Lerno, S. Wu, A. M. Marcobal, J. B. German, X. Chen, C. B. Lebrilla and D. A. Mills, *J. Biol. Chem.*, 2011, **286**, 11909.
- 2. H. Yu, H. Yu, R. Karpel and X. Chen, Bioorg. Med. Chem., 2004, 12, 6427.
- 3. G. Sugiarto, K. Lau, Y. Li, Z. Khedri, H. Yu, D. T. Le and X. Chen, Mol. Biosyst., 2011, 7, 3021.
- H. Yu, S. Huang, H. Chokhawala, M. Sun, H. Zheng and X. Chen, Angew. Chem. Int. Ed. Engl., 2006, 45, 3938.
- 5. J. Cheng, H. Yu, K. Lau, S. Huang, H. A Chokhawala, Y. Li, V. K. Tiwari and X. Chen, Glycobiology, 2008, **18**, 686.
- Y. Li, M. Xue, X. Sheng, H. Yu, J. Zeng, V. Thon, Y. Chen, M. M. Muthana, P. G. Wang and X. Chen, *Bioorg. Med. Chem.*, 2016, 24, 1696.
- 7. K. Lau, V. Thon, H. Yu, L. Ding, Y. Chen, M. M. Muthana, D. Wong, R. Huang and X. Chen, *Chem. Commun.*, 2010, **46**, 6066.
- J. Fang, J. Li, X. Chen, Y. Zhang, J. Wang, Z. Guo, W. Zhang, L. Yu, K. Brew and P. G. Wang, J. Am. Chem. Soc. 1998, 120, 6635.
- 9. S. W. Lin, T. M. Yuan, J. R. Li and C. H. Lin, Biochemistry, 2006, 45, 8108.
- G. Sugiarto, K. Lau, H. Yu, S. Vuong, V. Thon, Y. Li, S. Huang and X. Chen, *Glycobiology*, 2011, 21, 387.
- 11. M. M. Muthana, J. Qu, Y. Li, L. Zhang, H. Yu, L. Ding, H. Malekan and X. Chen, *Chem. Commun.*, 2012, **48**, 2728.
- 12. G. Zhao, W. Guan, L. Cai and P. G. Wang, Nat. Protoc., 2010, 5, 636.
- 13. Y. Zou, Z. Wu, L. Chen, X. Liu, G. Gu, M. Xue, P. G. Wang and M. Chen, *J. Carbohydr. Chem.*, 2012, **31**, 436.
- 14. J. Heimburg-Molinaro, X. Song, D. F. Smith and R. D. Cummings, *Curr. Protoc. Protein Sci.* 2011, ch 12: Unit 12.10.
- L. Byrd-Leotis, R. Liu, K. C. Bradley, Y. Lasanajak, S. F. Cummings, X. Song, J. Heimburg-Molinaro, S. E. Galloway, M. R. Culhane, D. F. Smith, D. A. Steinhauer and R. D. Cummings, *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**, E2241.
- 16. W. C. Wang and R. D. Cummings, J. Biol. Chem., 1988, 263, 4576.
- 17. N. Shibuya, I. J. Goldstein, W. F. Broekaert, M. Nsimba-Lubaki, B. Peeters and W. J. Peumans, J. Biol. Chem., 1987, 262, 1596.
- 18. Y. Itakura, S. Nakamura-Tsuruta, J. Kominami, N. Sharon, K. Kasai and J. Hirabayashi, *J. Biochem.*, 2007, **142**, 459.
- 19. J. Lescar, R. Loris, E. Mitchell, C. Gautier, V. Chazalet, V. Cox, L. Wyns, S. Perez, C. Breton and A. Imberty, *J. Biol. Chem.*, 2002, **277**, 6608.
- 20. J. T. Gallagher, A. Morris and T. M. Dexter, Biochem. J., 1985, 231, 115.
- 21. P. Parasuraman, V. Murugan, J. F. Selvin, M. M. Gromiha, K. Fukui and K. Veluraja, J. Mol. Recognit., 2014, 27, 482.
- 22. J. Heimburg-Molinaro, M. Tappert, X. Song, Y. Lasanajak, G. Air, D. F. Smith and R. D. Cummings, *Methods Mol. Biol.*, 2012, **808**, 251.